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and  biology  (27,  28).  Since 














(Figure  2B),  which  shares 
58%  identity  in  amino  acid 
sequence with Stx2 (29). SDF-1 













Changes in gene expression 




to  an  enzymatic  A  subunit, 
which depurinates eukaryotic 


















Stx have potent effects on endothelial cell metabolism and phenotype. HMVECs or HUVECs were treated 
with vehicle (Veh) or the indicated concentrations of (A) Stx2, (B) Stx1 B subunit alone (B) (1,000 fM), or 
holotoxin with a double mutation in the A subunit (A mut) (1,000 fM) for 24 hours. One hour before harvest, 
1 μCi [3H]leucine was added to assess de novo protein synthesis. Radioactivity incorporated into TCA-
precipitable material was quantitated, and data were normalized to vehicle-treated cells. The mean ± SEM 
of 14 experiments (HMVECs with Stx2), 5 experiments (HUVECs), or 3 experiments (mutants), triplicate 
determinations, is shown. (C) HMVECs (n = 6 replicates) were treated with Stx2 (10 fM, 24 hours) or vehicle 
and subjected to Affymetrix GeneChip gene expression profiling. By combining probe sets identified as dif-
ferentially expressed by all preprocessing algorithms and removing redundant probe sets, i.e., probe sets 
mapping to the same gene, it was determined that 86.2% of differentially expressed genes (318 out of 369 
unique genes) were upregulated by treatment with Stx. (D) The top 30 differentially expressed probe sets 
(based on magnitude of differential expression) were summarized in a heat map with hierarchical clustering. 
Processed signal intensities (computed using the mmgMOS preprocessing algorithm) are depicted on a log2 
scale, with rows representing differentially expressed probe sets and columns representing Stx- or vehicle-
treated samples. Note that several probe sets correspond to the same genes.
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indicate that the A subunit must be present and catalytically active 
to elicit changes in gene expression.





















The CXCR4/CXCR7/SDF-1 pathway is regulated specifically by Stx 























Stx activates the CXCR4/CXCR7/SDF-1 pathway 
in microvascular endothelium by a mechanism 
requiring enzymatic activity of the Stx A subunit. 
HMVECs were treated with the indicated concen-
trations of (A) Stx2 or (B) Stx1 for 6 or 24 hours, 
and mRNA levels were quantitated by qRT-PCR. 
(C) HMVECs were treated with 1,000 fM wild-type 
Stx2 (WT), Stx1 B subunit alone, or Stx2 holotox-
in consisting of a mutant A subunit and wild-type 
B subunit (A mut). mRNA levels were measured 
by qRT-PCR. In all cases, data are normal-
ized for GAPDH and 18S and are shown rela-
tive to vehicle-treated cells. Similar trends were 
observed whether or not data were normalized 
to housekeeping genes. Basal levels of CXCR4, 
CXCR7, and SDF1 were 1.53 ± 0.43 × 104, 
7.40 ± 2.20 × 104, and 2.21 ± 0.69 × 104 copies/
μg of input RNA, respectively. The mean ± SEM 
of at least 4 independent experiments is shown. 
*P < 0.05 vs. vehicle-treated cells.
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Stx enhances CXCR4 expression by both transcriptional 
and posttranscriptional mechanisms. (A) HMVECs treated 
with vehicle or 1,000 fM Stx2 for 20 hours were subjected 
to transcription arrest with 10 μg/ml actinomycin D, and 
RNA was harvested at various times thereafter. Remaining 
CXCR4 mRNA was determined using qRT-PCR and nor-
malized to 18S. The mean ± SEM of 3 independent experi-
ments is shown. Half-lives were calculated using exponen-
tial regression to be 1.18 ± 0.09 hours in vehicle-treated 
cells and 19.2 ± 7.8 hours in Stx-treated cells. (B) HMVECs 
were exposed to 1,000 fM Stx2 for 20 hours, followed by 
ChIP using anti-RNA polymerase II (Pol II) antibodies. qRT-
PCR for CXCR4 was then used to determine the amount 
of immunoprecipitated DNA (IP DNA). The mean ± SEM of 
at least 4 independent experiments is shown. (C) HMVECs 
were maintained under normoxic (21% O2) or hypoxic (<1% 
O2) conditions for the indicated times. qRT-PCR was used to 
determine mRNA levels. Data are normalized for 18S levels 
and are shown relative to normoxic cells. The mean ± SEM 
of 3 independent experiments is shown. Similar trends were 
observed whether or not data are normalized to housekeep-
ing genes. (D) Western blot analyses were performed for 
HIF-1α and HIF-2α in HMVECs treated with 10 fM or 1,000 
fM Stx for 6 or 24 hours. Lamin A/C was used as a loading 
control. Negative control and positive control were normoxic 
and hypoxic HMVECs. *P < 0.05 vs. vehicle or normoxia.
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Stx-treated cells exhibit increased CXCR4, CXCR7, and SDF1 transcripts associated with cellular polyribosomes. HMVECs were treated with 
vehicle or the indicated concentrations of Stx for 6 or 24 hours. Cellular ribosomes were fractionated based on density into 20 fractions, and RNA 
was purified from each fraction. mRNA levels were quantitated by qRT-PCR, normalized for luciferase mRNA, and shown relative to vehicle 
fraction no. 1. 80S refers to 80S ribosome. (A) CXCR4, (B) CXCR7, (C) SDF1, and (D) cyclophilin A. A representative experiment is shown.
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lab strain, C57BL/6, no phenotype was observed; however, knock-



















































































Functional effects of Stx and the CXCR4/CXCR7/SDF-1 axis on 
endothelial permeability. (A) Confluent endothelial monolayers were 
grown on transwell filters and treated with the indicated concentrations 
of Stx. Stx treatment causes increased dextran leak and decreased 
electrical resistance across the monolayer. The mean ± SEM of at least 
3 independent experiments is shown. (B) Treatment of HMVECs with 
SDF-1 (50 ng/ml, 5 hours) induces dextran leak. The mean ± SEM of 
at least 3 independent experiments is shown. (C) Stx-induced HMVEC 
permeability is decreased by treatment of AMD3100/plerixafor. A repre-
sentative experiment of 3 is shown (mean ± SD). *P < 0.05, **P < 0.001 
vs. vehicle-treated cells.
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Stx challenge causes impaired renal function and mortality in vivo. (A) CAST/Ei mice were injected i.v. with wild-type Stx2 (3,125 pg/g), Stx2 
A subunit mutant (10 times LD50), or Stx1 B subunit (50 times LD50), and survival was monitored for 10 days. (B) Mice were injected with Stx2 
(2,400 pg/g) and, at the indicated times, animals were perfused with fluorescent microbeads. A representative confocal image of a 100-μm sec-
tion is shown (original magnification, ×5). Plasma collected from Stx-treated animals shows elevated (C) creatinine and (D) urea and reduced 
(E) bicarbonate levels by 4 days after Stx injection. Mice injected with Stx had (F) significantly higher urine albumin/creatinine ratios by 4 days 
after Stx injection, (G) lower urine creatinine, and (H) slightly elevated urine albumin. Horizontal bars indicate the median values, boxes indicate 
25th to 75th percentiles, and whiskers indicate the minimum and maximum values. (I) Mice injected with Stx or PBS were injected i.v. with 0.1% 
Evans Blue dye. Urine samples were collected 1 hour later, and the amount of dye leak was measured spectrophotometrically. (J) Transmission 
electron micrographs of glomeruli from control and Stx-treated animals. *P < 0.05, **P < 0.001 vs. day 0 or PBS control.
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Effects of Stx on animal hematology and gastrointestinal biology. (A) 
CAST/Ei mice were injected i.v. with Stx2 (2,400 pg/g) on day 0. Blood 
samples were taken via saphenous vein at the indicated times. (A) 
Hematocrit (HCT) and (B) platelet levels are shown (n = 13 per time 
point). (C–E) Approximately 60% of mice develop gastrointestinal 
hemorrhage. (C) Gross images of stomach and small intestine from 
PBS- and Stx-treated mice. (D) H&E staining shows intraluminal hem-
orrhage (original magnification, ×50) and (E) intramucosal hemorrhage 
(arrows; original magnification, ×100). **P < 0.001.
Figure 8
Stx challenge causes dysregulation of SDF-1 in vivo. (A) SDF-1 in 
situ hybridization and immunohistochemistry demonstrate increased 
SDF-1 production in the renal cortical tubules (original magnifica-
tion, ×160). (B) The number of tubules staining positive for SDF-1 by 
immunohistochemistry were quantified in 6 nonoverlapping cortical 
fields (magnification, ×100). (C) Animals were injected with Stx2 (2,400 
pg/g) on day 0, and SDF-1α levels were measured in blood plasma 
at the indicated times. Horizontal bars indicate the mean, and each 
symbol represents an individual animal. *P < 0.01.
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Blockade of CXCR4/SDF-1 interaction by AMD3100 improves renal 
function and promotes animal survival. (A) CAST/Ei mice were injected 
with Stx2 (2,400 pg/g) on day 0, followed by daily administration of 
AMD3100 (10 μg/g) or an equal volume of PBS beginning 1 day after 
Stx. Survival was monitored for 10 days (n = 26 per treatment group). 
(B and C) CAST/Ei mice were injected with Stx2 (625 pg/g) on day 0, 
followed by daily injections of AMD3100 (10 μg/g) or an equivalent 
volume of PBS vehicle. Plasma was collected 4 days after Stx injec-
tion and analyzed for (B) creatinine and (C) urea (n = 10–26 animals 
per group). Horizontal bars indicate the median values, boxes indi-
cate 25th to 75th percentiles, and whiskers indicate the minimum and 
maximum values. *P < 0.05.
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Blockade of CXCR4/SDF-1 interaction by AMD3100 restores platelet levels in vivo and inhibits platelet adhesion to endothelial cells under flow 
conditions in vitro. (A) Blood smears from Adamts13–/– mice injected with Stx2 (625 pg/g) show evidence of red blood cell fragments 4 days after 
Stx exposure, with high numbers of reticulocytes (original magnification, ×150). (B) Adamts13–/– mice were injected with Stx2 (625 pg/g) on day 0, 
followed by daily injections of AMD3100 (10 μg/g) or PBS. Blood was analyzed for platelet levels prior to Stx injection and again at day 4 after toxin 
injection in both groups (n = 9–21 animals per group). *P < 0.05 vs. control animals that received neither Stx nor AMD3100. (C) HMVECs were 
grown to confluence in microfluidic channels and were either left untreated or were treated with 10 fM Stx2 (24 hours), after which calcein-labeled 
platelets were perfused at constant shear rates of 2.5 dyn/cm2 over the endothelial monolayer. Preincubation of HMVECs with AMD3100 (10 μM) 
significantly inhibited platelet adhesion. Images are representative of 5 independent experiments (original magnification, ×15). (D) Quantification 
of platelet adhesion to endothelial cells. Data are expressed as mean ± SEM from 5 independent experiments. *P < 0.05; **P < 0.01.
Downloaded on October 17, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/57313
research article
































































































Circulating SDF-1 levels in HUS patients. SDF-1 levels were measured in plas-
ma samples from individuals infected with E. coli O157:H7. (A) Infected sam-
ples obtained from patients with uncomplicated O157:H7 infection within 4 days 
after the onset of diarrhea (n = 36). Horizontal bars indicate the median values, 
boxes indicate 25th to 75th percentiles, and whiskers indicate the minimum and 
maximum values. Pre-HUS, samples collected prior to HUS diagnosis in those 
individuals who later progressed to HUS (n = 7); HUS, samples collected on the 
day of HUS diagnosis (n = 22). *P < 0.05. (B) SDF-1 levels over the course of 
E. coli O157:H7–mediated illness. Each line represents 1 patient, and the last 
data point for each patient was obtained on the day of HUS diagnosis.
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Affymetrix GeneChip expression profiling — sample preparation, 
























Data preprocessing and determination of differential expression. Raw probe-
level  intensities were preprocessed using 13 different computational 

























































RNA polymerase II ChIP assays
ChIP was performed as previously described (75). Briefly, 5 μg anti–poly-
merase II antibody (N-20; Santa Cruz Biotechnology Inc.) was added to 
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the platelets were still under flow, and the fluorescent intensity of adhered 
platelets was quantified using the Bioflux 200 analysis software.
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